An Overview on Recent Analytical Methodologies for the Determination of Antiobesity Glucagon like Peptides-1 Receptor Agonists

Document Type : Review articles

Authors

1 Department of pharmaceutical chemistry, faculty of pharmacy, Delta University for Science and Technology. Coastal international road, Gamasa, Mansoura, Egypt

2 Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

3 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Delta University for Science and Technology

Abstract

Recently, glucagon-like peptide 1 (GLP-1) has received significant attention in the treatment of obesity and diabetes due to its potent incretin effect. Unique unimolecular peptides with several functions have surfaced as one of the most promising therapeutic strategies to improve metabolic efficiency and return body weight to normal. The diabetes.co.uk platform, for instance, indicates that “obesity is believed to account for 80-85% of the risk of developing type 2 diabetes”.type 2 diabetes has indeed more to do with lifestyle – as well as, more generally, ageing demographics – hence its labelling as an obesity comorbidity.

The US Food and Drug Administration (FDA) has currently approved the following GLP-1-based medications: liraglutide, semaglutide, and tirzepatide for long term management of obesity. This paper investigates published analytical techniques that have been documented in the literature thus far for measuring anti-obesity tides in pharmaceutical formulations and biologic samples. These encompass a range of methodologies, such as capillary electrophoresis, spectrophotometry, liquid chromatography-electrospray ionization-tandem mass spectrometry, high-performance thin layer chromatography, and electrochemical approaches.

Keywords

Main Subjects

Delta University Scientific Journal
Volume 7, Issue 2
September 2024
Pages 17-23

Files

Share

How to cite

Statistics